Skip to content
Peptide research

KPV

Also known as Alpha-MSH Fragment
Category
Immune & Defense
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A tripeptide fragment of the hormone alpha-MSH, marketed for gut and skin inflammation and mucosal healing. Its anti-inflammatory mechanism (blocking the NF-kB pathway) is characterized in cell and animal models, and no human clinical trials or safety studies have been completed. The FDA has stated it lacks human exposure and safety data. Most supply is unregulated research-grade product of uncertain purity, and it is not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Intestinal anti-inflammatory activity

    Medium

    Mouse colitis models show reduced colonic inflammation and tissue damage.

  • NF-kB pathway inhibition

    Medium

    Blocks NF-kB and MAPK inflammatory signaling at nanomolar concentrations in cell studies.

  • Pro-inflammatory cytokine reduction

    Medium

    Lowers IL-1beta, IL-6, TNF-alpha, and IFN-gamma while sparing anti-inflammatory IL-10.

Evidence limits

Evidence Level
Preclinical

100% of evidence is from cell culture and animal models. No human safety, pharmacokinetic, or efficacy data exists. FDA has stated it lacks human exposure data on KPV. Multiple rodent colitis models show consistent anti-inflammatory efficacy.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active infection requiring immune response

    Moderate

    KPV's strong anti-inflammatory action via NF-kB suppression may impair immune defense during active infection.

  • Organ transplant recipients

    Moderate

    Immune-modulating properties may interact with immunosuppressive regimens unpredictably.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data for this MSH-derived peptide.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Zero human clinical trials or safety studies completed

    High
  • FDA has explicitly stated it lacks human exposure/safety data on KPV

    High
  • Theoretical immunosuppression risk

    Theoretical
  • Contraindicated in pregnancy, breastfeeding, cancer history

    Low
  • Research-grade products may have purity/contamination issues

    Moderate
  • Long-term effects unknown

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.